Thats exactly right Chips
I referred to this basically
- to demonstrate how an announcement can move a share price
- to show how much optionality Starpharma has with Dep Program. I do not follow PAB......nor have an inclination to do any research of company
- to establish the fact 0f this announcement talking about trials in animals....whereas Starpharma conducting clinical trials with humans
So let me remind all of you
Starpharma has over 100 patents.......imagine how great that is........over 75% of all oncology drugs can use and possibly better outcomes in efficacy and life expectations.
This has been shown in several preclinical trials and demonstrated in ongoing human trials
AstraZeneca's drug AZD0466 was not able to go forward without Starpharma's technology. It was far too toxic.....and this is where the DEP tech stepped in
Jackie's words in recent commsec interview
OUR ASTRAZENECA PARTNERSHIP HAS REALLY GONE FROM STRENGTH TO STRENGTH AND CONTINUES TO MOVE ALONG IN A VERY POSITIVE MANNER
ASTRAZENECA'S DRUG IS A REALLY EXCITING CANCER DRUG AND HAS SHOWN EXCELLENT EFFIFACY
RELATIONSHIP CONTINUES TO GROW AND PROSPER
3 ACTIVE PROGRAMS AND WE ARE IN DISCUSSIONS WITH THEM ABOUT THE POTENTIAL TO EXPAND THAT
PARTNERSHIPS NOT YET IN THE PUBLIC DOMAIN. THEY ARE LONG TERM RELATIONSHIPS
ASTRAZENECA RECENTLY FILED PATENTS WHICH INCORPORATE DEP TECHNOLOGY ( I would think this has been the holdup getting the drug AZD0466 into phase 1)
IN DISCUSSIONS WITH THEM ....YOU KNOW.....THE POTENTIAL TO EXPAND THAT (Jackie repeated these words 2 times in interview and in my opinion.....her body language indicated she wanted to say something and held back. Could that have been the reason for Pascal's visit to Starpharma offices)
What was the quote from Mene Pangalos (Executive Vice President of AstraZeneca's Innovative Medicines and Early Development Biotech Unit) concerning Pascal Soiret's (CEO of AstraZeneca) visit to Starpharma offices last week
"Great to see our CEO visiting one of our wonderful partners down under, one of the pioneers of nanoparticle technology"
In regards to the VivaGel BV formulation
The last module will be completed within the next month or so ......with approval from FDA sometime late in the year
She indicated the market of treating BV globally was $750 million....with the USA market taking about 50-55 %
Jackie also said there is absolutely no treatment for long term treatment to prevent the recurrent form of disease. Starpharma's VivaGel BV formulation is a first in class for this billion dollar market
I felt the interview clarified a few things
The share price is now 55 percent below Bell Potters target of $1.86
It really does not matter how long we need to wait.....but as most posters say we are now on the home straight
Remember when MSB was in the $1.20's and woosh almost hit $2
Well I reckon the same is about to happen to Starpharma.......but in a more dramatic way
- Forums
- ASX - By Stock
- Starpharma and Glioblastoma and Dep Docetaxel and Patrys
Thats exactly right Chips I referred to this basically to...
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M |
Open | High | Low | Value | Volume |
10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 83046 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 83046 | 0.105 |
3 | 198569 | 0.100 |
1 | 10111 | 0.099 |
3 | 483557 | 0.096 |
1 | 824859 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 30000 | 1 |
0.115 | 122753 | 4 |
0.120 | 221197 | 6 |
0.125 | 30000 | 1 |
0.130 | 138570 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online